Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges.

Lanuti P, Simeone P, Rotta G, Almici C, Avvisati G, Azzaro R, Bologna G, Budillon A, Di Cerbo M, Di Gennaro E, Di Martino ML, Diodato A, Doretto P, Ercolino E, Falda A, Gregorj C, Leone A, Losa F, Malara N, Marini M, Mastroroberto P, Mollace V, Morelli M, Muggianu E, Musolino G, Neva A, Pierdomenico L, Pinna S, Piovani G, Roca MS, Russo D, Scotti L, Tirindelli MC, Trunzo V, Venturella R, Vitagliano C, Zullo F, Marchisio M, Miscia S.

Sci Rep. 2018 Apr 11;8(1):5823. doi: 10.1038/s41598-018-24234-0.

2.

Toxigenic effects of two benthic diatoms upon grazing activity of the sea urchin: morphological, metabolomic and de novo transcriptomic analysis.

Ruocco N, Costantini S, Zupo V, Lauritano C, Caramiello D, Ianora A, Budillon A, Romano G, Nuzzo G, D'Ippolito G, Fontana A, Costantini M.

Sci Rep. 2018 Apr 4;8(1):5622. doi: 10.1038/s41598-018-24023-9.

3.

HDAC inhibition potentiates immunotherapy in triple negative breast cancer.

Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN.

Oncotarget. 2017 Dec 12;8(69):114156-114172. doi: 10.18632/oncotarget.23169. eCollection 2017 Dec 26.

4.

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.

Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, Muto P, Delrio P, Avallone A, Budillon A, Di Gennaro E.

J Exp Clin Cancer Res. 2017 Dec 6;36(1):177. doi: 10.1186/s13046-017-0647-5.

5.

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.

Iannelli F, Lombardi R, Milone MR, Pucci B, De Rienzo S, Budillon A, Bruzzese F.

Recent Pat Anticancer Drug Discov. 2017 Nov 29. doi: 10.2174/1574892812666171129141211. [Epub ahead of print]

PMID:
29189178
6.

An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer.

Polo A, Nittoli C, Crispo A, Langastro T, Cocco S, Severino L, De Laurentiis M, Ciliberto G, Montella M, Budillon A, Costantini S.

Mol Biosyst. 2017 Nov 21;13(12):2687-2696. doi: 10.1039/c7mb00489c.

PMID:
29072741
7.

Conformational analysis of the human chemokine receptor CXCR3.

Raucci R, Polo A, Budillon A, Colonna G, Costantini S.

Mol Immunol. 2017 Dec;92:76-86. doi: 10.1016/j.molimm.2017.10.010. Epub 2017 Oct 17.

PMID:
29054054
8.

Environment and bladder cancer: molecular analysis by interaction networks.

Polo A, Crispo A, Cerino P, Falzone L, Candido S, Giudice A, De Petro G, Ciliberto G, Montella M, Budillon A, Costantini S.

Oncotarget. 2017 May 26;8(39):65240-65252. doi: 10.18632/oncotarget.18222. eCollection 2017 Sep 12.

9.

Evaluating the Effects of an Organic Extract from the Mediterranean Sponge Geodia cydonium on Human Breast Cancer Cell Lines.

Costantini S, Guerriero E, Teta R, Capone F, Caso A, Sorice A, Romano G, Ianora A, Ruocco N, Budillon A, Costantino V, Costantini M.

Int J Mol Sci. 2017 Oct 9;18(10). pii: E2112. doi: 10.3390/ijms18102112.

10.

Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches.

Leone A, Roca MS, Ciardiello C, Costantini S, Budillon A.

Oxid Med Cell Longev. 2017;2017:2597581. doi: 10.1155/2017/2597581. Epub 2017 Jul 9. Review.

11.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4671-4672. doi: 10.1038/onc.2017.212. Epub 2017 Jun 19.

PMID:
28628115
12.

Different strategies for mechanical VENTilation during CardioPulmonary Bypass (CPBVENT 2014): study protocol for a randomized controlled trial.

Bignami E, Guarnieri M, Saglietti F, Maglioni EM, Scolletta S, Romagnoli S, De Paulis S, Paternoster G, Trumello C, Meroni R, Scognamiglio A, Budillon AM, Pota V, Zangrillo A, Alfieri O.

Trials. 2017 Jun 7;18(1):264. doi: 10.1186/s13063-017-2008-2.

13.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4573-4584. doi: 10.1038/onc.2017.75. Epub 2017 Apr 3. Erratum in: Oncogene. 2017 Jun 19;:.

PMID:
28368399
14.

Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis.

Pecori B, Lastoria S, Caracò C, Celentani M, Tatangelo F, Avallone A, Rega D, De Palma G, Mormile M, Budillon A, Muto P, Bianco F, Aloj L, Petrillo A, Delrio P.

PLoS One. 2017 Jan 6;12(1):e0169462. doi: 10.1371/journal.pone.0169462. eCollection 2017.

15.

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.

Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A.

BMC Cancer. 2016 Nov 25;16(1):918.

16.

Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles.

Russo A, Maiolino S, Pagliara V, Ungaro F, Tatangelo F, Leone A, Scalia G, Budillon A, Quaglia F, Russo G.

Oncotarget. 2016 Nov 29;7(48):79670-79687. doi: 10.18632/oncotarget.13216.

17.

Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles.

Sorice A, Siano F, Capone F, Guerriero E, Picariello G, Budillon A, Ciliberto G, Paolucci M, Costantini S, Volpe MG.

Molecules. 2016 Oct 21;21(10). pii: E1411.

18.

Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.

Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A.

Amino Acids. 2017 Mar;49(3):517-528. doi: 10.1007/s00726-016-2338-5. Epub 2016 Oct 19.

PMID:
27761756
19.

Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents.

Zotti AI, Di Gennaro E, Corvino A, Frecentese F, Magli E, Perissutti E, Cirino G, Roviezzo F, Terranova-Barberio M, Iannelli F, Caliendo G, Santagada V, Fiorino F, Budillon A, Severino B.

Anticancer Agents Med Chem. 2017;17(7):973-981. doi: 10.2174/1871520616666160926120904.

PMID:
27671294
20.

Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.

Milone MR, Pucci B, Colangelo T, Lombardi R, Iannelli F, Colantuoni V, Sabatino L, Budillon A.

Mol Oncol. 2016 Oct;10(8):1344-62. doi: 10.1016/j.molonc.2016.07.006. Epub 2016 Jul 25.

21.

Management of non-small cell lung cancer in the era of personalized medicine.

Rocco G, Morabito A, Leone A, Muto P, Fiore F, Budillon A.

Int J Biochem Cell Biol. 2016 Sep;78:173-179. doi: 10.1016/j.biocel.2016.07.011. Epub 2016 Jul 15. Review.

PMID:
27425397
22.

Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells.

Russo A, Pellosi DS, Pagliara V, Milone MR, Pucci B, Caetano W, Hioka N, Budillon A, Ungaro F, Russo G, Quaglia F.

Int J Pharm. 2016 Sep 10;511(1):127-139. doi: 10.1016/j.ijpharm.2016.06.118. Epub 2016 Jun 29.

PMID:
27374195
23.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial.

Avallone A, Budillon A.

J Clin Oncol. 2016 May 1;34(13):1564. doi: 10.1200/JCO.2015.66.1512. Epub 2016 Mar 7. No abstract available.

PMID:
26951321
24.

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.

Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, Votino C, Pancione M, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V.

Cell Death Dis. 2016 Feb 25;7:e2120. doi: 10.1038/cddis.2016.28.

25.

The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells.

Colangelo T, Polcaro G, Ziccardi P, Muccillo L, Galgani M, Pucci B, Milone MR, Budillon A, Santopaolo M, Mazzoccoli G, Matarese G, Sabatino L, Colantuoni V.

Cell Death Dis. 2016 Feb 25;7:e2108. doi: 10.1038/cddis.2016.29.

26.

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.

Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C, Di Gennaro E, Ciliberto G, Roscilli G, Aurisicchio L, Marra E, Mancini R, Budillon A, Leone A.

Oncotarget. 2016 Apr 12;7(15):19559-74. doi: 10.18632/oncotarget.7195.

27.

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).

Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A.

BMC Cancer. 2016 Feb 8;16:69. doi: 10.1186/s12885-016-2102-y.

28.

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E.

Oncotarget. 2016 Feb 16;7(7):7715-31. doi: 10.18632/oncotarget.6802.

29.

Support Detection for SAR Tomographic Reconstructions from Compressive Measurements.

Budillon A, Schirinzi G.

ScientificWorldJournal. 2015;2015:949807. doi: 10.1155/2015/949807. Epub 2015 Oct 1.

30.

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.

Leone A, Roca MS, Ciardiello C, Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di Gennaro E, Bruzzese F, Budillon A.

Free Radic Biol Med. 2015 Dec;89:287-99. doi: 10.1016/j.freeradbiomed.2015.07.155. Epub 2015 Sep 26.

PMID:
26409771
31.

Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.

Avallone A, Pecori B, Bianco F, Aloj L, Tatangelo F, Romano C, Granata V, Marone P, Leone A, Botti G, Petrillo A, Caracò C, Iaffaioli VR, Muto P, Romano G, Comella P, Budillon A, Delrio P.

Oncotarget. 2015 Oct 6;6(30):30394-407. doi: 10.18632/oncotarget.4724.

32.

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.

Bizzarro V, Belvedere R, Milone MR, Pucci B, Lombardi R, Bruzzese F, Popolo A, Parente L, Budillon A, Petrella A.

Oncotarget. 2015 Sep 22;6(28):25076-92. doi: 10.18632/oncotarget.4725.

33.

Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood.

Lanuti P, Rotta G, Almici C, Avvisati G, Budillon A, Doretto P, Malara N, Marini M, Neva A, Simeone P, Di Gennaro E, Leone A, Falda A, Tozzoli R, Gregorj C, Di Cerbo M, Trunzo V, Mollace V, Marchisio M, Miscia S.

Cytometry A. 2016 Mar;89(3):259-70. doi: 10.1002/cyto.a.22730. Epub 2015 Aug 25.

34.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. No abstract available.

PMID:
26151329
35.

A perspective on the current treatment strategies for locally advanced rectal cancer.

Avallone A, Aloj L, Aprile G, Rosati G, Budillon A.

Int J Biochem Cell Biol. 2015 Aug;65:192-6. doi: 10.1016/j.biocel.2015.06.002. Epub 2015 Jun 6. Review.

PMID:
26055517
36.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):827. Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b.

37.

Pathophysiologically relevant in vitro tumor models for drug screening.

Das V, Bruzzese F, Konečný P, Iannelli F, Budillon A, Hajdúch M.

Drug Discov Today. 2015 Jul;20(7):848-55. doi: 10.1016/j.drudis.2015.04.004. Epub 2015 Apr 20. Review.

PMID:
25908576
38.

Ascending aortic graft thrombosis from an endoluminal candida albicans infection.

Nicolini F, Budillon AM, Borrello B, Gherli T.

Eur J Cardiothorac Surg. 2015 May;47(5):e233-4. doi: 10.1093/ejcts/ezv092. Epub 2015 Mar 1. No abstract available.

PMID:
25732970
39.

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.

Milone MR, Pucci B, Bifulco K, Iannelli F, Lombardi R, Ciardiello C, Bruzzese F, Carriero MV, Budillon A.

Oncotarget. 2015 Mar 10;6(7):5324-41.

40.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

41.

Indices of methylation in sperm DNA from fertile men differ between distinct geographical regions.

Consales C, Leter G, Bonde JP, Toft G, Eleuteri P, Moccia T, Budillon A, Jönsson BA, Giwercman A, Pedersen HS, Ludwicki JK, Zviezdai V, Heederik D, Spanò M.

Hum Reprod. 2014 Sep;29(9):2065-72. doi: 10.1093/humrep/deu176. Epub 2014 Jul 17.

PMID:
25035434
42.

Exposure to perfluoroalkyl substances and sperm DNA global methylation in Arctic and European populations.

Leter G, Consales C, Eleuteri P, Uccelli R, Specht IO, Toft G, Moccia T, Budillon A, Jönsson BA, Lindh CH, Giwercman A, Pedersen HS, Ludwicki JK, Zviezdai V, Heederik D, Bonde JP, Spanò M.

Environ Mol Mutagen. 2014 Aug;55(7):591-600. doi: 10.1002/em.21874. Epub 2014 Jun 3.

PMID:
24889506
43.

Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15.

Bruzzese F, Hägglöf C, Leone A, Sjöberg E, Roca MS, Kiflemariam S, Sjöblom T, Hammarsten P, Egevad L, Bergh A, Ostman A, Budillon A, Augsten M.

Cancer Res. 2014 Jul 1;74(13):3408-17. doi: 10.1158/0008-5472.CAN-13-2259. Epub 2014 Apr 29.

44.

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.

Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.

Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17.

PMID:
24345738
45.

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.

Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A.

Cell Death Dis. 2013 Oct 24;4:e878. doi: 10.1038/cddis.2013.406.

46.

New perspective for an old antidiabetic drug: metformin as anticancer agent.

Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A.

Cancer Treat Res. 2014;159:355-76. doi: 10.1007/978-3-642-38007-5_21. Review.

PMID:
24114491
47.

Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.

Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A.

Expert Opin Drug Saf. 2014 Jan;13(1):113-29. doi: 10.1517/14740338.2014.845167. Epub 2013 Oct 5. Review.

PMID:
24093908
48.

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A.

Cell Death Dis. 2013 May 23;4:e641. doi: 10.1038/cddis.2013.165. Erratum in: Cell Death Dis. 2014;5:e1276.

49.

Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies?

Avallone A, Aloj L, Delrio P, Pecori B, Leone A, Tatangelo F, Perri F, Petrillo A, Scott N, Budillon A.

Anticancer Agents Med Chem. 2013 Jul 1;13(6):852-60.

PMID:
23272969
50.

Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.

Avallone A, Aloj L, Caracò C, Delrio P, Pecori B, Tatangelo F, Scott N, Casaretti R, Di Gennaro F, Montano M, Silvestro L, Budillon A, Lastoria S.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1848-57. doi: 10.1007/s00259-012-2229-2. Epub 2012 Oct 5.

PMID:
23053320

Supplemental Content

Loading ...
Support Center